Karthik Ramasamy
MBBS FRCP FRCPath PhD
Associate Professor of Haematology & Consultant Haematologist
- Cancer Research Divisional Lead, Thames Valley & South Midlands
- Myeloma Lead, Thames Valley Cancer Alliance
- Trustee, Myeloma UK Patient Charity
MRC CARP Fellow
Improving outcomes for patients with plasma cell dyscrasias
Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust and Associate Professor of Haematology, Radcliffe Department of Medicine, Oxford UK. Dr Ramasamy is the Director of the Oxford Myeloma Translational Research Centre https://oxford-myeloma.org.uk, and a Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Cancer Alliance Group. He is the Divisional Lead for Cancer research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK and leads the National Haemonc Oversight Specialty group. He is an Executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance. Karthik serves on the Myeloma UK Board, a patient charity exclusively dealing with myeloma advocacy and research. Dr Ramasamy with collaborators is developing a national advisory service for Castleman disease. Dr Ramasamy completed his haematology training in London. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London. Dr Ramasamy is a Chief Investigator of myeloma studies and his academic research interests are early diagnosis of myeloma, myeloma renal, bone disease and myeloma drug resistance mechanisms. Karthik has published over 100 papers and authored textbooks/ chapters on myeloma
Recent publications
-
Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.
Kaiser M. et al, (2024), Br J Haematol
-
Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil
Hungria V. et al, (2024), Cancers, 16
-
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Lee HC. et al, (2024), Eur J Haematol
-
Challenges in designing and running smouldering myeloma interventional clinical trials.
Lecat C. et al, (2024), EJHaem, 5, 418 - 420
-
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Ramasamy K. et al, (2024), Haematologica